|
|
| |
| The Brain’s Own Immune Cells Are Stealing Your Sleep |
| Sleep falls apart in Alzheimer’s. Most researchers blamed the plaques — those sticky protein clumps that pile up between nerve cells. But a team at the University of Kentucky just showed that the real problem may be something else entirely. It’s the brain’s own defense system. |
| Let me explain. Your brain has immune cells called microglia — think of them as a cleanup crew. They patrol for damage, clear debris, and keep things running. But when microglia detect amyloid plaques, they don’t just tidy up. They overreact. They flood the area with inflammatory signals. And that inflammation keeps the brain wired and awake. |
| Shannon Macauley and Nicholas Constantino at Kentucky’s Sanders-Brown Center on Aging tested this idea in mice bred to develop Alzheimer’s-like plaques. They gave the animals a drug called pexidartinib that wiped out roughly 87% of their microglia. The plaques stayed. Every single one. But the mice gained more than two hours of sleep per day — and they spent far more time in deep, restorative non-REM sleep. |
| |
The plaques didn’t shrink. Sleep got better anyway. That’s a big deal. It means the immune reaction to the plaques — not the plaques themselves — may be driving one of Alzheimer’s most disabling symptoms. |
|
| One more surprise. Sleep problems in these mice appeared early and never got worse — even as plaques doubled. Macauley calls it a “ceiling effect.” The initial immune flare set the damage. More plaques didn’t pile on more insomnia. That suggests early intervention could matter most. |
| I could be wrong, of course. This is mice, not men. And you can’t just strip the immune cells out of a living human brain. But I believe this finding reshapes how we think about sleep and Alzheimer’s. If the inflammation is the engine, calming it — rather than chasing plaques — could give millions of people better nights. |
| I urge you to pay attention to this one. It’s a direction worth watching. |
| Macauley & Constantino · University of Kentucky · Alzheimer’s & Dementia · June 7, 2026 |
|
|
|
|
| |
| The 10-Minute Post-Meal Walk |
| Every time you eat, your blood sugar rises. That’s normal. But when it spikes hard and crashes fast, your brain pays a price. Repeated glucose spikes damage small blood vessels. They feed inflammation. And over years, they nudge the brain toward insulin resistance — the very pattern some researchers call “type 3 diabetes.” |
| You don’t need a drug to blunt those spikes. You need your legs. |
| Loretta DiPietro at George Washington University found that 15 minutes of light walking after a meal cuts post-meal glucose surges. A 2025 study confirmed that even 10 minutes works — dropping peak blood sugar from about 182 to 164 milligrams per deciliter. Your muscles soak up glucose when they move. So a short walk right after eating pulls sugar out of your blood before it can spike. |
| The Protocol |
| When |
| Within 5 minutes of finishing a meal — start with your largest meal of the day |
| Duration |
| 10 to 15 minutes at an easy pace — no need to break a sweat |
| Rules |
| Flat ground is fine. Around the block, down a hallway, even pacing your yard. Don’t wait 30 minutes — sooner is better. If you can do it after two or three meals a day, even better. |
| |
| You may notice you feel sharper in the afternoon on days you walk after lunch. That’s the glucose steadying out. I urge you to try it for one week and see what changes. |
|
|
|
|
|
|
|
| A Probiotic Mix Lowered an Alzheimer’s Blood Marker in 24 Weeks |
| Eighty-seven older adults in South Korea with early signs of cognitive trouble took either a three-strain probiotic blend or a placebo for six months. The probiotic group saw a drop in a blood marker called phosphorylated tau 181 — a protein fragment that rises before Alzheimer’s symptoms appear. They also scored better on tests of visual memory and spatial reasoning. The study is small and short. But the gut-to-brain connection keeps showing up in trial after trial. |
| Seo et al. · Journal of Alzheimer’s Disease · August 2026 |
|
|
| High-Dose Vitamin D Linked to More Than 13% Better Cognitive Scores in At-Risk Adults |
| Emory University studied 54 adults who had both mild cognitive impairment — the stage between normal aging and dementia — and disrupted sleep. Those taking higher daily doses of vitamin D scored more than 13% better on a standard cognitive test than those taking none. This was a small observational study, not a controlled trial. But it adds to a growing body of work suggesting vitamin D may matter most for people already showing early signs of decline. |
| Emory University · Sleep Medicine · 2026 |
|
|
| Variety of Social Activities May Matter More Than Frequency |
| A large international study found that older adults who took part in a wider range of social activities — volunteering, group hobbies, community events, not just one repeated habit — showed slower cognitive decline over time. The key word is “diverse.” Doing the same thing every week helped less than mixing it up. The authors suggest a broader range of social activities provides cumulative neurocognitive stimulation, reinforcing neural networks over time. |
| Journal of Epidemiology & Community Health · October 2026 |
|
|
|
|
| |
| 158 drugs are in clinical trials for Alzheimer’s and related dementias right now. Most will fail. But three developments from the past two weeks caught my eye — each one attacking the disease from a different angle. |
|
| Testing a Diabetes Drug and an ADHD Drug Against Alzheimer’s — at the Same Time |
| A new UK platform trial called AD-SMART just started recruiting. Led by the UK Dementia Research Institute and Alzheimer’s Research UK, it tests multiple drugs against one shared placebo group — which could cut trial time in half. The first two arms use metformin (a common diabetes pill that may calm brain inflammation) and atomoxetine (an attention-deficit drug that targets norepinephrine, a brain chemical tied to focus and memory). Neither was built for Alzheimer’s. Both showed early signals in smaller studies. This trial is designed to get answers faster. |
| Multi-arm Phase 2/3 · Recruiting now · October 2026 |
|
|
| Blocking Hallucinations in Lewy Body Dementia Without Heavy Sedation |
| Cognition Therapeutics announced that the FDA aligned on a pivotal Phase 3 trial for zervimesine, also called CT1812, in dementia with Lewy bodies. Lewy body dementia causes vivid hallucinations and delusions, and current treatments often sedate patients heavily. Zervimesine works differently — it blocks a receptor on brain cells that lets toxic proteins latch on and cause damage. If it succeeds, it would be the first long-term treatment to target the root disease rather than just masking symptoms. |
| Phase 3 · FDA-aligned · October 22, 2026 |
|
|
| Lowering Cholesterol to See if It Slows Early Alzheimer’s |
| NewAmsterdam Pharma dosed the first patient in its SPINOZA trial late last month. The drug is obicetrapib, a cholesterol-lowering pill. Earlier data from NewAmsterdam showed it reduced a key Alzheimer’s blood marker in people who carry the APOE4 risk gene — the strongest known genetic risk factor for late-onset Alzheimer’s. SPINOZA will test whether the drug can slow the disease in people who have early brain changes but no symptoms yet. The link between cholesterol, blood vessel health, and brain decline is one of the most watched areas in the field. |
| Phase 2b · First patient dosed · September 29, 2026 |
|
|
